NFKB1 and T-cell large granular lymphocyte leukemia: Administration of the PI3K inhibitor LY294002 also resulted in significantly decreased NF-kB activity in T-LGLL cells as well as cell apoptosis, and one of two LGLL patients treated on a phase I study of the dual PI3K δ/γ inhibitor duvelisib had a prolonged partial response (3, 60).